Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A first-in-class Parkinson's treatment just got the FDA's stamp of approval. Tavapadon (Juvmo), a once-daily oral D1/D5 dopamine receptor partial agonist made by AbbVie, is now approved for adults with Parkinson's disease — both as a standalone therapy and alongside levodopa. It's the first dopamine agonist to target D1-like receptors, with the hope of delivering motor benefits while sidestepping some of the side effects tied to older agents.
A first-in-class Parkinson's treatment just got the FDA's stamp of approval. Tavapadon (Juvmo), a once-daily oral selective D1/D5 dopamine receptor partial agonist developed by AbbVie, has been approved for adults with Parkinson's disease (PD). It's the first dopamine agonist to selectively target the D1-like receptor family — rather than the D2/D3 receptors targeted by existing agents — and can be used with or without levodopa. AbbVie expects it to be available in the US by October 2026.
The approval rests on the phase 3 TEMPO trial program. In early PD, tavapadon consistently outperformed placebo on combined motor function scores. In patients already on levodopa with motor fluctuations, it added over an hour of "ON time" without troublesome involuntary movements. That said, no trials directly compared tavapadon to levodopa or existing dopamine agonists, so its relative edge remains an open question.
By the Numbers:
Why it matters: Levodopa has been the cornerstone of PD treatment for over 50 years, but long-term use can lead to motor complications. Tavapadon's novel mechanism offers a potentially differentiated option — though real-world data, especially in patients over 80 (who were excluded from pivotal trials), will be key to understanding its true place in therapy.
